Dual-specificity phosphatases as targets for antineoplastic agents

Nature Reviews Drug Discovery

Volumn 1, Issue 12, 2002, Pages 961-976

  Lyon, Michael A ^a   Ducruet, Alexander P ^b   Wipf, Peter ^a   Lazo, John S ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BENZOQUINONE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; CYCLODEPSIPEPTIDE; DNACIN A1; DNACIN B1; DYSIDIOLIDE; MENADIONE; NAPHTHOQUINONE; NOCARDINONE A; NOCARDINONE B; ORGANOPHOSPHATE; PHOSPHOLIPID DERIVATIVE; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; QUINONE DERIVATIVE; RK 682; SERINE; SESQUITERPENE DERIVATIVE; SESQUITERPENOID; STEVASTELIN A; STEVASTELIN B; SULFIRCIN; TETRONIC ACID DERIVATIVE; THREONINE; TYROSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ENZYME INHIBITOR;

ANIMAL CELL; BIOCHEMISTRY; CANCER CELL CULTURE; CELL CYCLE; CELL DEATH; CELL PROLIFERATION; CHEMICAL BOND; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INDUSTRY; DRUG ISOLATION; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOLECULAR BIOLOGY; NOCARDIA; NONHUMAN; PENICILLIUM; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN HYDROLYSIS; REVIEW; SIGNAL TRANSDUCTION; SPONGE (PORIFERA); STREPTOMYCES; STRESS; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN-TYROSINE-PHOSPHATASE;

EID: 0036884693     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd963     Document Type: Review

References (123)

1. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discov. 1, 493-502 (2002).
2. Hunter, T. Signalling - 2000 and beyond. Cell 100, 113-127 (2000).
3. Tonks, N. K. & Neel, B. G. From form to function: signaling by protein tyrosine phosphatases. Cell 87, 365-368 (1996).
4. Stone, R. L. & Dixon, J. E. Protein-tyrosine phosphatases. J. Biol. Chem. 269, 31323-31326 (1994).
5. Zolnierowicz, S. & Bollen, M. Protein phosphorylation and protein phosphatases. EMBO J. 19, 483-488 (2000).
6. Denu, J. M., Stuckey, J. A., Saper, M. A. & Dixon, J. E. Form and function in protein dephosphorylation. Cell 87, 361-364 (1996).
7. Egloff, M. P., Cohen, P. T., Reinemer, P. & Barford, D. Crystal structure of the catalytic subunit of human protein phosphatase 1 and its complex with tungstate. J. Mol. Biol. 254, 942-959 (1995).
8. Zhang, Z. Y. Protein-tyrosine phosphatases: biological function, structural characteristics, and mechanism of catalysis. Crit. Rev. Biochem. Mol. Biol. 33, 1-52 (1998).
9. Barford, D., Flint, A. J. & Tonks, N. K. Crystal structure of human protein tyrosine phosphatase 1B. Science 263, 1397-1404 (1994).
10. Yuvaniyama, J., Denu, J. M., Dixon, J. E. & Saper, M. A. Crystal structure of the dual specificity protein phosphatase VHR. Science 272, 1328-1331 (1996).
11. Todd, J. L., Tanner, K. G. & Denu, J. M. Extracellular regulated kinases (ERK)1 and ERK2 are authentic substrates for the dual-specificity protein-tyrosine phosphatase VHR. A novel role in down-regulating the ERK pathway. J. Biol. Chem. 274, 13271-13280 (1999).
12. Gautier, J., Solomon, M. J., Booher, R. N., Bazan, J. F. & Kirschner, M. W. cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2. Cell 67, 197-211 (1991).
13. Kumagai, A. & Dunphy, W. G. The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system. Cell 64, 903-914 (1991).
14. Strausfeld, U. et al. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 351, 242-245 (1991).
15. + functions as an inducer in the mitotic control of fission yeast. Cell 45, 145-153 (1986).
16. + protein kinase regulates entry into mitosis. Nature 342, 39-45 (1989).
17. Galaktionov, K. & Beach, D. Specific activation of cdc25 tyrosine phosphatases by B-type cyclins: evidence for multiple roles of mitotic cyclins. Cell 67, 1181-1194 (1991).
18. Sadhu, K., Reed, S. I., Richardson, H. & Russell, P. Human homolog of fission yeast Cdc25 mitotic inducer is predominantly expressed in G2. Proc. Natl Acad. Sci. USA 87, 5139-5143 (1990).
19. + gene occurs in humans and is highly expressed in some cancer cells. New Biol. 3, 959-968 (1991).
20. Jinno, S. et al. Cdc25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 13, 1549-1556 (1994).
21. Wegener, S., Hampe, W., Herrmann, D. & Schaller, H. C. Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur. J. Cell Biol. 79, 810-815 (2000).
22. Forrest, A. R. et al. Multiple splicing variants of cdc25B regulate G2/M progression. Biochem. Biophys. Res. Commun. 260, 510-515 (1999).
23. Draetta, G. & Eckstein, J. Cdc25 protein phosphatases in cell proliferation. Biochim. Biophys. Acta 1332, M53-M63 (1997).
24. Gottlin, E. B. et al. Kinetic analysis of the catalytic domain of human CDC25B. J. Biol. Chem. 271, 27445-27449 (1996).
25. Chen, W., Wilborn, M. & Rudolph, J. Dual-specific Cdc25B phosphatase: in search of the catalytic acid. Biochemistry 39, 10781-10789 (2000).
26. Fauman, E. B. et al. Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A. Cell 93, 617-625 (1998).
27. 2-terminal domain in the catalysis and substrate binding of human Cdc25. J. Biol. Chem. 271, 5118-5124 (1996).
28. Reynolds, R. A. et al. Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle. J. Mol. Biol. 293, 559-568 (1999).
29. Coqueret, O., Berube, G. & Nepveu, A. The mammalian Cut homeodomain protein functions as a cell-cycle-dependent transcriptional repressor which downmodulates p21WAF1/CIP1/SDI1 in S phase. EMBO J. 17, 4680-4694 (1998).
30. Xia, K. et al. Tyrosine phosphorylation of the protooncoprotein Raf-1 is regulated by Raf-1 itself and the phosphatase Cdc25A. Mol. Cell. Biol. 19, 4819-4824 (1999).
31. Wilborn, M., Free, S., Ban, A. & Rudolph, J. The C-terminal tail of the dual-specificity Cdc25B phosphatase mediates modular substrate recognition. Biochemistry 40, 14200-14206 (2001).
32. Hoffmann, I., Clarke, P. R., Marcote, M. J., Karsenti, E. & Draetta, G. Phosphorylation and activation of human CDC25C by CDC2-cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J. 12, 53-63 (1993).
33. Strausfeld, U. et al. Activation of p34cdc2 protein kinase by microinjection of human CDC25C into mammalian cells. Requirement for prior phosphorylation of CDC25C by p34CDC2 on sites phosphorylated at mitosis. J. Biol. Chem. 269, 5989-6000 (1994).
34. Baldin, V., Cans, C., Knibiehler, M. & Ducommun, B. Phosphorylation of human CDC25B phosphatase by CDK1-cyclin A triggers its proteasome-dependent degradation. J. Biol. Chem. 272, 32731-32734 (1997).
35. Cans, C., Ducommun, B. & Baldin, V. Proteasome-dependent degradation of human CDC25B phosphatase. Mol. Biol. Rep. 26, 53-57 (1999).
36. Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J. & Lukas, J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847 (2001).
37. Mailand, N. et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 288, 1425-1429 (2000).
38. Bernardi, R., Liebermann, D. A. & Hoffman, B. Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 19, 2447-2454 (2000).
39. Molinari, M., Mercurio, C., Dominguez, J., Goubin, F. & Draetta, G. F. Human Cdc25A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep. 1, 71-79 (2000).
40. Davezac, N. et al. Regulation of CDC25B phosphatases subcellular localization. Oncogene 19, 2179-2185 (2000).
41. Forrest, A. & Gabrielli, B. Cdc25B activity is regulated by 14-3-3. Oncogene 20, 4393-4401 (2001).
42. Graves, P. R., Lovly, C. M., Uy, G. L. & Piwinica-Worms, H. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene 20, 1839-1851 (2001).
43. Mils, V. et al. Specific interaction between 14-3-3 isoforms and the human CDC25B phosphatase. Oncogene 19, 1257-1265 (2000).
44. Furnari, B., Rhind, N. & Russell, P. CDC25 mitotic inducer targeted by CHK1 DNA damage checkpoint kinase. Science 277, 1495-1497 (1997).
45. Lopez-Girona, A., Furnari, B., Mondesert, O. & Russell, P. Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein. Nature 397, 172-175 (1999).
46. Peng, C. Y. et al. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277, 1501-1505 (1997).
47. Conklin, D. S., Galaktionov, K. & Beach, D. 14-3-3 proteins associate with cdc25 phosphatases. Proc. Natl Acad. Sci. USA 92, 7892-7896 (1995).
48. Galaktionov, K., Jessus, C. & Beach, D. Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. Genes Dev. 9, 1046-1058 (1995).
49. Hoffmann, I., Draetta, G. & Karsenti, E. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J., 13, 4302-4310 (1994).
50. + encodes a protein phosphatase that dephosphorylates p34cdc2. Mol. Biol. Cell 3, 73-84 (1992).
51. Millar, J. B., McGowan, C. H., Lenaers, G., Jones, R. & Russell, P. p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. EMBO J. 10, 4301-4309 (1991).
52. Honda, R., Ohba, Y., Nagata, A., Okayama, H. & Yasuda, H. Dephosphorylation of human p34cdc2 kinase on both Thr-14 and Tyr-15 by human cdc25B phosphatase. FEBS Lett. 318, 331-334 (1993).
53. Gabrielli, B. G. et al. Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J. Cell. Sci. 109 (Part 5), 1081-1093 (1996).
54. Sebastian, B., Kakizuka, A. & Hunter, T. Cdc25M2 activation of cyclin-dependent kinases by dephosphorylation of threonine-14 and tyrosine-15. Proc. Natl Acad. Sci. USA 90, 3521-3524 (1993).
55. Vincent, I. et al. Constitutive Cdc25B tyrosine phosphatase activity in adult brain neurons with M phase-type alterations in Alzheimer's disease. Neuroscience 105, 639-650 (2001).
56. Nurse, P. A long twentieth century of the cell cycle and beyond. Cell 100, 71-78 (2000).
57. Rhind, N., Furnari, B. & Russell, P. Cdc2 tyrosine phosphorylation is required for the DNA damage checkpoint in fission yeast. Genes Dev. 11, 504-511 (1997).
58. Blasina, A. et al. A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase. Curr. Biol. 9, 1-10 (1999).
59. Sanchez, Y. et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277, 1497-1501 (1997).
60. Bulavin, D. V. et al. Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase. Nature 411, 102-107 (2001).
61. Chan, T. A., Hermeking, H., Lengauer, C., Kinzler, K. W. & Vogelstein, B. 14-3-3σ is required to prevent mitotic catastrophe after DNA damage. Nature 401, 616-620 (1999).
62. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57-70 (2000).
63. Galaktionov, K. et al. CDC25 phosphatases as potential human oncogenes. Science 269, 1575-1577 (1995).
64. Cangi, M. G. et al. Role of the Cdc25A phosphatase in human breast cancer J. Clin. Invest. 106, 753-761 (2000).
65. Dixon, D., Moyana, T. & King, M. J. Elevated expression of the cdc25A protein phosphatase in colon cancer. Exp. Cell Res. 240, 236-43 (1998).
66. Gasparotto, D. et al. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res. 57, 2366-2368 (1997).
67. Hernandez, S. et al. CDC25A and the splicing variant CDC25B2, but not CDC25B1, -B3 or -C, are overexpressed in aggressive human non-Hodgkin's lymphomas. Int. J. Cancer 89, 148-52 (2000).
68. Hu, Y. C., Lam, K. Y., Law, S., Wong, J. & Srivastava, G. Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin. Cancer Res. 7, 3519-3525 (2001).
69. Kudo, Y. et al. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn. J. Cancer Res. 88, 947-952 (1997).
70. Sato, Y. et al. Expression of the cdc25B mRNA correlated with that of N-myc in neuroblastoma. Jpn. J. Clin. Oncol. 31, 428-431 (2001).
71. Wu, W., Fan, Y. H., Kemp, B. L., Walsh, G. & Mao, L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 58, 4082-5 (1998).
72. Sandhu, C. et al. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells. Oncogene 19, 5314-5323 (2000).
73. Vogt, A. et al. Spatial analysis of key signaling proteins by high-content solid-phase cytometry in Hep3B cells treated with an inhibitor of Cdc25 dual-specificity phosphatases. J. Biol. Chem. 276, 20544-20550 (2001).
74. Kar, S. & Carr, B. I. Growth inhibition and protein tyrosine phosphorylation in MCF 7 breast cancer cells by a novel K vitamin. J. Cell. Physiol. 185, 386-393 (2000).
75. Pumiglia, K. M. & Decker, S. J. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc. Natl Acad. Sci. USA 94, 448-452 (1997).
76. Stanciu, M. et al. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J. Biol. Chem. 275, 12200-12206 (2000).
77. Zou, X. et al. The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1. Mol. Cell. Biol. 21, 4818-4828 (2001).
78. Ma, Z. Q., Liu, Z., Ngan, E. S. & Tsai, S. Y. Cdc25B functions as a novel coactivator for the steroid receptors. Mol. Cell. Biol. 21, 8056-8067 (2001).
79. Imoto, M. et al. Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. I. Taxonomy, isolation, and characterization. J. Antibiot. (Tokyo) 46, 1342-1346 (1993).
80. Eckstein, J. W. Cdc25 as a potential target of anticancer agents. Invest. New Drugs 18, 149-156 (2000).
81. Tanida, S., Hasegawa, T., Muroi, M. & Higashide, E. Dnacins, new antibiotics. I. Producing organism, fermentation, and antimicrobial activities. J. Antibiot. (Tokyo) 33, 1443-1448 (1980).
82. Horiguchi, T. et al. Dnacin A1 and dnacin B1 are antitumor antibiotics that inhibit cdc25B phosphatase activity. Biochem. Pharmacol. 48, 2139-2141 (1994).
83. Gunasekera, S. P., McCarthy, P. J., KellyBorges, M., Lobkovsky, E. & Clardy, J. Dysidiolide: a novel protein phosphatase inhibitor from the Caribbean sponge Dysidea etheria de Laubenfels. J. Am. Chem. Soc. 118, 8759-8760 (1996).
84. Blanchard, J. L., Epstein, D. M., Boisclair, M. D., Rudolph, J. & Pal, K. Dysidiolide and related γ-hydroxy butenolide compounds as inhibitors of the protein tyrosine phosphatase, CDC25. Bioorg. Med. Chem. Lett. 9, 2537-2538 (1999).
85. Takahashi, M. et al. Synthesis of the novel analogues of dysidiolide and their structure-activity relationship. Bioorg. Med. Chem. Lett. 10, 2571-2574 (2000).
86. Hamaguchi, T., Sudo, T. & Osada, H. RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at G1 phase. FEBS Lett. 372, 54-58 (1995).
87. Hamaguchi, T., Masuda, A., Morino, T. & Osada, H. Stevastelins, a novel group of immunosuppressants, inhibit dual-specificity protein phosphatases. Chem. Biol. 4, 279-286 (1997).
88. Morino, T. et al. Structural determination of stevastelins, novel depsipeptides from Penicillium sp. J. Antibiot. (Tokyo) 49, 564-568 (1996).
89. Wright, A. E., McCarthy, P. J. & Schulte, G. K. Sulfircin - a new sesterterpene sulfate from a deep-water sponge of the genus Ircinia. J. Org. Chem. 54, 3472-3474 (1989).
90. Cebula, R. E., Blanchard, J. L., Boisclair, M. D., Pal, K. & Bockovich, N. J. Synthesis and phosphatase inhibitory activity of analogs of sulfircin. Bioorg. Med. Chem. Lett. 7, 2015-2020 (1997).
91. Nutter, L. M. et al, Meradione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. Biochem. Pharmacol. 41, 1283-1292 (1991).
92. Ham, S. W., Park, H. J. & Lim, D. H. Studies on menadione as an inhibitor of the cdc25 phosphatase. Bioorg. Chem. 25, 33-36 (1997).
93. Tamura, K. et al. Cdc25 inhibition and cell cycle arrest by a synthetic thioalkyl vitamin K analogue. Cancer Res. 60, 1317-1325 (2000).
94. Otani, T. et al. New Cdc25B tyrosine phosphatase inhibitors, nocardiones A and B, produced by Nocarota sp. TP-A0248: taxonomy, fermentation, isolation, structural elucidation and biological properties. J. Antibiot. (Tokyo) 53, 337-344 (2000).
95. Loukaci, A. et al. Coscinosulfate, a CDC25 phosphatase inhibitor from the sponge Coscinoderma mathewsi. Bioorg. Med. Chem. 9, 3049-3054 (2001).
96. Nishikawa, Y. et al. Growth inhibition of hepatoma cells induced by vitamin K and its analogs. J. Biol. Chem. 270, 28304-28310 (1995).
97. Ham, S. W. et al. Naphthoquinone analogs as inactivators of cdc25 phosphatase. Bioorg. Med. Chem. Lett. 8, 2507-2510 (1998).
98. Koufaki, M. et al. Alkyl and alkoxyethyl antineoplastic phospholipids. J. Med. Chem. 39, 2609-2614 (1996).
99. Sodeoka, M., Sampe, R., Kagamizono, T. & Osada, H. Asymmetric synthesis of RK-682 and its analogs, and evaluation of their protein phosphatase inhibitory activities. Tetrahedron Lett. 37, 8775-8778 (1996).
100. Sodeoka, M. et al. Synthesis of a tetronic acid library focused on inhibitors of tyrosine and dual-specificity protein phosphatases and its evaluation regarding VHR and cdc25B inhibition. J. Med. Chem. 44, 3216-3222 (2001).
101. Boukouvalas, J., Cheng, Y. X. & Robichaud, J. Total synthesis of (+)-dysidiolide. J. Org. Chem. 63, 228-229 (1998).
102. Brohm, D. & Waldmann, H. Stereoselective synthesis of the core structure of the protein phosphatase inhibitor dysidiolide. Tetrahedron Lett. 39, 3995-3998 (1998).
103. Corey, E. J. & Roberts, B. E. Total synthesis of dysidiolide. J. Am. Chem. Soc. 119, 12425-12431 (1997).
104. Demeke, D. & Forsyth, C. J. Novel total synthesis of the anticancer natural product dysidiolide. Org. Lett. 2, 3177-3179 (2000).
105. Jung, M. E. & Nishimura, N. Enantioselective formal total synthesis of (-)-dysidiolide. Org. Lett. 3, 2113-2115 (2001).
106. Magnuson, S. R., Sepp-Lorenzino, L., Rosen, N. & Danishefsky, S. J. A concise total synthesis of dysidiolide through application of a dioxolenium-mediated Diels-Alder reaction. J. Am. Chem. Soc. 120, 1615-1616 (1998).
107. Miyaoka, H., Kajiwara, Y. & Yamada, Y. Synthesis of marine sesterterpenoid dysidiolide. Tetrahedron Lett. 41, 911-914 (2000).
108. Piers, E., Caille, S. & Chen, G. A formal total synthesis of the sesterterpenoid (+/-)-dysidiolide and approaches to the syntheses of (+/-)-6-epi-, (+/-)-15-epi-, and (+/-)-6,15-bis-epi-dysidiolide. Organic Lett. 2, 2483-2486 (2000).
109. Takahashi, M., Dodo, K., Hashimoto, Y. & Shirai, R. Concise asymmetric synthesis of dysidiolide. Tetrahedron Lett. 41, 2111-2114 (2000).
110. Brohm, D. et al. Natural products are biologically validated starting points in structural space for compound library development: solid-phase synthesis of dysidiolide-derived phosphatase inhibitors. Angew. Chem. Int. Edn Engl. 41, 307-311 (2001).
111. Peng, H., Zalkow, L. H., Abraham, R. T. & Powis, G. Novel CDC25A phosphatase inhibitors from pyrolysis of 3-α-azido-B-homo-6-oxa-4-cholesten-7-one on silica gel. J. Med. Chem. 41, 4677-4680 (1998).
112. Peng, H. et al. Steroidal derived acids as inhibitors of human Cdc25A protein phosphatase. Bioorg. Med. Chem. 8, 299-306 (2000).
113. Peng, H. et al. Syntheses and biological activities of a novel group of steroidal derived inhibitors for human Cdc25A protein phosphatase. J. Med. Chem. 44, 834-848 (2001).
114. Wipf, P., Cunningham, A., Rice, R. L. & Lazo, J. S. Combinatorial synthesis and biological evaluation of library of small-molecule Ser/Thr protein phosphatase inhibitors. Bioorg. Med. Chem. 5, 165-177 (1997).
115. Rice, R. L. et al. A targeted library of small-molecule, tyrosine, and dual-specificity phosphatase inhibitors derived from a rational core design and random side chain variation. Biochemistry 36, 15965-15974 (1997).
116. Tamura, K., Rice, R. L., Wipf, P. & Lazo, J. S. Dual G1 and G2/M phase inhibition by SC-ααδ9, a combinatorially derived Cdc25 phosphatase inhibitor. Oncogene 18, 6989-6996 (1999).
117. Ducruet, A. P. et al. Identification of new Cdc25 dual specificity phosphatase inhibitors in a targeted small molecule array. Bioorg. Med. Chem. 8, 1451-1466 (2000).
118. Wipf, P., Aslan, D. C., Southwick, E. C. & Lazo, J. S. Sulfonylated aminothiazoles as new small molecule inhibitors of protein phosphatases. Bioorg. Med. Chem. Lett. 11, 313-317 (2001).
119. Bergnes, G. et al. Generation of an Ugi library of phosphate mimic-containing compounds and identification of novel dual specific phosphatase inhibitors. Bioorg. Med. Chem. Lett. 9, 2849-2854 (1999).
120. Fritzen, F. L., Brightwell, A. S., Erickson, L. A. & Romero, D. L. The solid phase synthesis of tetrahydroisoquinolines having cdc25B inhibitory activity. Bioorg. Med. Chem. Lett. 10, 649-652 (2000).
121. El-Subbagh, H. I., Abadi, A. H., Al-Khawad, I. E. & Al-Rashood, K. A. Synthesis and antitumor activity of some new substituted quinolin-4-one and 1,7-naphthyridin-4-one analogs. Archiv. der Pharmazie 332, 19-24 (1999).
122. Lazo, J. S. et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. J. Med. Chem. 44, 4042-4049 (2001).
123. Lazo, J. S. et al. Identification of a potent and selective pharmacophore for Cdc25 dual specificity phosphatase inhibitors. Mol. Pharmacol. 61, 720-728 (2002).